Advertisement

Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!

Published:March 01, 2022DOI:https://doi.org/10.1016/j.ejca.2022.01.011

      Highlights

      • In the sixth month after the first dose, patients with a positive serological status were 86.3%.
      • IgG titer was inferior in patients than in healthcare workers due to a more rapid decline.
      • The estimated time to reach negative serological status was 11.3 months for patients.

      Abstract

      Introduction

      We previously reported on the immunogenicity and safety of BNT162b2 in a large cohort of patients with cancer after the first and second doses (Di Noia et al., 2021) [1]. Herein, we present result after six months of follow-up.

      Methods

      This prospective study included patients affected by solid tumors and afferent to our institution who received two doses of BNT162b2 vaccine. A cohort of vaccinated healthcare workers (HCW) was used as control-group. Both cohorts were evaluated for the titer of anti-Spike (S) IgG at prefixed time-points (TPs). Time-point 4 was scheduled at 24–26 weeks after the second dose.

      Results

      In the current analysis, 400 patients and 232 healthcare workers were evaluated. Responders (IgG > 15 AU/mL) in patients group were 86.5% compared with 94.4% among healthcare workers. Also the IgG titer at TP4 was significantly inferior in patients than in healthcare workers (70.81 vs 134.64 AU/ml, p < 0.001). There was a more rapid decline of the antibody level from TP3 to TP4 in patients than in healthcare workers (1.78 vs 1.3 fold). The estimated IgG half-life was significantly shorter for patients (73 days) than in healthcare workers (118 days) as well as the time to reach negative serological status (340 vs 532 days).

      Conclusion

      The decline of humoral response to the vaccine observed in patients with solid cancer after six months from the first dose support the urgent need of an early additional dose.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Di Noia V.
        • Pimpinelli F.
        • Renna D.
        • et al.
        Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution.
        Clin Cancer Res. 2021; 2439 (2021 Sep 28;clincanres. [Online ahead of print])https://doi.org/10.1158/1078-0432.CCR-21-2439
        • Di Noia V.
        • Pimpinelli F.
        • Renna D.
        • et al.
        Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer.
        Ann Oncol Nov. 2021; 29 ([Online ahead of print])https://doi.org/10.1016/j.annonc.2021.11.015
        • Cohn
        • et al.
        SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.
        Science. 2021; https://doi.org/10.1126/science.abm0620
        • Di Noia V.
        • Renna D.
        • Barberi V.
        • et al.
        The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: early data from a single-institute survey.
        Eur J Cancer. 2021 Aug; 153: 260-264https://doi.org/10.1016/j.ejca.2021.05.006

      Linked Article